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Abstract
Background: Low-dose computed tomography (CT) for lung cancer screening can reduce lung cancer mortality. The
National Lung Screening Trial reported a 20% reduction in lung cancer mortality in high-risk smokers. However, CT scanning
is extremely sensitive and detects non-calcified nodules (NCNs) in 24–50% of subjects, suggesting an unacceptably high
false-positive rate. We hypothesized that by reviewing demographic, clinical and nodule characteristics, we could identify
risk factors associated with the presence of nodules on screening CT, and with the probability that a NCN was malignant.
Methods: We performed a longitudinal lung cancer biomarker discovery trial (NYU LCBC) that included low-dose CT-
screening of high-risk individuals over 50 years of age, with more than 20 pack-year smoking histories, living in an urban
setting, and with a potential for asbestos exposure. We used case-control studies to identify risk factors associated with the
presence of nodules (n=625) versus no nodules (n=557), and lung cancer patients (n=30) versus benign nodules (n=128).
Results: The NYU LCBC followed 1182 study subjects prospectively over a 10-year period. We found 52% to have NCNs
.4 mm on their baseline screen. Most of the nodules were stable, and 9.7% of solid and 26.2% of sub-solid nodules
resolved. We diagnosed 30 lung cancers, 26 stage I. Three patients had synchronous primary lung cancers or multifocal
disease. Thus, there were 33 lung cancers: 10 incident, and 23 prevalent. A sub-group of the prevalent group were stable for
a prolonged period prior to diagnosis. These were all stage I at diagnosis and 12/13 were adenocarcinomas.
Conclusions: NCNs are common among CT-screened high-risk subjects and can often be managed conservatively. Risk
factors for malignancy included increasing age, size and number of nodules, reduced FEV1 and FVC, and increased pack-
years smoking. A sub-group of screen-detected cancers are slow-growing and may contribute to over-diagnosis and lead-
time biases.
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Introduction
Over 94 million current and former smokers are at increased
risk for lung cancer, and might benefit from an effective screening
test for early detection. [1,2] The challenge is to develop a
screening strategy that will identify a small lung nodule, and
specify whether the nodule is malignant before micro-metastasis
occurs [3,4]. Using data from Surveillance, Epidemiology and
End-Results (SEER) Registries, estimates are that 70% of lung
cancer deaths could be averted if the cancer was diagnosed at an
early stage [5–7].
The evidence from chest computed tomography (CT) screening
studies conducted since the 1990’s show that the scans can detect
early lung cancer, but at the cost of false-positive nodules in more
than 25% of those screened [8–12]. Most studies have been non-
randomized, so demonstrating a mortality benefit of CT screening
has been difficult. Most recently, however, the National Lung
Screening Trial (NLST) found that screening with low-dose chest
CTs can decrease lung cancer mortality by 20% compared to
chest radiograph screening [13]. However, over 24% of screens
were positive for non-calcified nodules (NCNs); more than 96% of
these were found to be false-positive results on follow-up.
If we can develop an improved risk-profile to guide CT
screening protocols–both to refine who should be screened and to
determine which patients with nodules should be followed most
closely–we could reduce the cost and anxiety associated with CT
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reassuring patients at decreased risk of malignancy. In 2001 the
NYU Lung Cancer Biomarker Center (LCBC) began a lung
cancer biomarker discovery and validation project, which included
low-dose CT-scans at regular intervals. The project’s goal was to
evaluate biomarkers to determine lung cancer risk and to
differentiate benign from malignant nodules. The NYU cohort
differed from those in previously reported CT screening studies.
The population was urban, with a risk of asbestos exposure due to
referrals from a local utility workers’ union. Since our study design
focused on the collection of material for biomarker discovery, we
invited participants to return for screening even if CT-scans
identified no suspicious findings or nodules remained stable for
more than 3 years. Therefore, we have a prolonged follow-up
period, with serial CT-scans for up to 10 years.
In this paper, we review the demographic, clinical, and
radiographic characteristics of individuals with nodules on their
initial CT compared to individuals with no nodules, and of our
patients diagnosed with lung cancer compared to subjects with
presumed-benign NCNs. Our hypothesis was that we would
identify risk factors for the presence of nodules on screening CT
and for the probability that a nodule identified on CT represents
an early lung cancer.
Methods
Human Subjects and Ethics Statement
The Institutional Review Board (IRB) for NYU Langone
Medical Center and the Bellevue Research Committee (BRC) of
Bellevue Hospital Center approved the research. All participants
signed written consent forms. Between March 2001 and June 2010
the NYU LCBC recruited 1182 study subjects over 50 years of age
with more than 20 pack-years of smoking history. Recruitment
included mailings to NYU physicians, presentations to the NYU
occupational medicine department and the utility workers’ union
of Con Edison, advertisements, and distribution of flyers.
Individuals with a prior cancer history or history of chemotherapy
were excluded, although those with basal or squamous cell
carcinoma of the skin were eligible. Clinic visits included a
respiratory, medical and exposure questionnaire; collecting
peripheral blood samples; forced expiratory spirometry conducted
and analyzed according to ATS Standards [14]; induced sputum
using aerosolized saline; and low-radiation-dose CT screening.
The questionnaire was a validated ATS respiratory questionnaire
that included 115 questions on demographic characteristics,
tobacco use, occupation and occupational exposures, alcohol
use, family history, medical history, and respiratory symptoms.
Screening CT Imaging and Nodule Follow-up Protocols
During the course of this decade-long study, a number of
different Siemens CT scanners were employed. Initially, we used a
4 detector CT-scanner (Siemens Volume-Zoom Multidetector
Scanner, Foecheim, Germany). Using low-dose technique (40–
80 mAs) 7 mm-thick sections were acquired and then reconstruct-
ed every 6 mm, with the additional acquisition of select high
resolution 1 mm images through suspected lung nodules. Subse-
quently, 16 and 64 detector scanners were used, and with the
improved scan capability, the format for obtaining scans was
changed. In most cases, 5 mm-thick images were acquired and
images were reconstructed every 5 mm, using 1 mm collimation.
This technique allowed simultaneous prospective reconstruction of
contiguous 1 mm images, obviating the need for additional image
acquisitions to perform high-resolution detailed analysis of nodule
characteristics and calcification. Maximum bidirectional diameters
in the axial plane were measured using electronic calipers. Scans
were interpreted by thoracic radiologists and, when abnormalities
were present, reviewed by a pulmonologist.
Nodule follow-up protocols were modified during the course of
the study based on increasing awareness of the need to minimize
radiation exposure. If no NCNs were identified, participants were
invited to return for repeat screening annually for the first 3 years
of the study, and then every 2 years. If new nodules were identified
on initial or repeat screening, a standard nodule follow-up
protocol was followed. Follow-up was performed initially accord-
ing to guidelines proposed by the ELCAP study [9,10];
subsequently, according to the Fleischner Society guidelines
[15]. Specifically, non-calcified nodules over 8 mm and suspicious
for cancer were referred for immediate clinical evaluation,
including possible PET scans, biopsy, resection or further close
observation, based on clinical judgment. For nodules 6–8 mm, a
follow-up CT scan was performed at 3–6 months, then at 9–12
months, and then at 24 months if no changes were identified. For
nodules 4–6 mm, follow-up CT was done at 6–12 months and at
18–24 months if there were no changes. If a solid nodule was
stable over time, in size and appearance, for more than 2 years, it
was considered benign. Participants were then invited to continue
annual or biennial screening. Sub-solid nodules over 6 mm were
never classified as benign, and, after 2-year stability, continued CT
follow up at 2 year intervals was recommended indefinitely. Since
this was a biomarker discovery project, participants were allowed
to return to the study at any point, even if they had not followed
the recommendations for follow-up.
The radiologists also noted the presence of other radiographic
abnormalities. Emphysema was assessed visually as areas of low
attenuation contrasting with surrounding parenchyma with
normal attenuation. Findings suggestive of asbestos exposure,
including pleural thickening or plaques and parenchymal fibrosis
consistent with asbestosis (e.g. bilateral, lower lobe irregular
opacities), received particular attention.
For each CT scan, the investigators prepared a written report
containing detailed radiologic findings and final summary
interpretations. CT scan data was entered into the study database
by a pulmonologist–listing up to 6 nodules (as per the initial
ELCAP definition to define diffuse lung disease), their locations,
and for each nodule, solid versus sub-solid opacification. Sub-solid
nodules included ground-glass as well as part solid, part ground-
glass lesions. The presence or absence of emphysema and other
radiographic findings were recorded. The clinical study nurse, the
screening coordinator, and the database coordinator kept track of
all study participants with non-calcified nodules, and of all lung
cancer diagnoses and their follow-ups.
Statistical Methods
This report is based on two case-control studies. First, to identify
risk factors for the presence of nodules on initial screening CT, we
compared cases, defined as individuals with NCNs over 4 mm, to
controls, defined as high-risk individuals with no nodules on CT-
scan. Second, to identify risk factors associated with increased risk
of malignancy in patients found to have NCN on screening CT,
we compared cases, defined as patients diagnosed with lung
cancer, to controls, defined as individuals with presumed-benign
NCNs which either resolved or remained stable for more than 3
years. We chose to exclude individuals with sub-solid nodules over
4 mm from the control group, even if they were stable, since we
could not be certain that these did not represent malignancy
[16,17]. We did include stable sub-solid nodules less than 5 mm
and sub-solid nodules that resolved in the control group.
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(age, gender, race, BMI), medical, family and exposure history,
respiratory symptoms, CT findings (nodules, emphysema, asbes-
tos-related changes), and PFT results. For each of the variables, we
summarized the distributions with descriptive statistics that
included mean, median, range and standard deviation for
quantitative variables and frequency distributions for qualitative
variables. Risk factors associated with nodules versus no nodules
and cancers versus benign nodules were identified in separate
analyses. Nodules (both solid and sub-solid) were classified based
on changes over time (increased, decreased or remained stable).
Univariable analyses were conducted to estimate the association of
potential risk factors with nodule status and behavior; odds ratios
were estimated along with associated 95% confidence intervals
and Cochran Mantel Haenszel chi square test statistics were
computed. Stepwise polytomous logistic regression methods were
used to evaluate the contribution to risk of demographic factors,
smoking related factors, and history of other diseases. Stratification
was also used to control for possible confounding factors and
interaction terms were incorporated. For the lung cancer patients,
we used nonparametric comparisons to examine possible differ-
ences between cancer patients and individuals with presumed
benign nodules.
Results
Demographic and Clinical Characteristics at Enrollment
All 1182 participants had a baseline CT screen; 819 (70%) had
at least one follow-up CT by the end of the study period (Figure 1).
Those that did not have follow-ups were individuals with no
nodules on initial CT who chose not to return or individuals who
were not yet due for follow-up by the end of the study period. The
average length of follow up was 43.4 months (range 0–113). The
demographics of the screened cohort on enrollment are presented
in Table 1. There were approximately equal numbers of men and
women, the mean age was 63, and the majority of the participants
were white. This finding is partially due to our recruitment from a
utility workers’ union, and may also reflect possible barriers to
recruitment to cancer-related screening studies among minority
populations [18]. Participants were heavy smokers (mean pack-
years was 42); more than half of the participants were current
smokers at enrollment. Almost 20% of participants had a first-
degree relative with a history of lung cancer. Persistent respiratory
symptoms were common in this population (Table 1), but
pulmonary function was preserved (Table 2). Emphysema was
present on the CT-scans of 35.6%.
There were 201 individuals referred from Con Edison, most of
whom had direct occupational or nearby bystander asbestos
exposure based on their job descriptions. Of these, 65 had pleural
plaques, pleural thickening, and/or fibrosis consistent with
asbestosis (bilateral lower lobe irregular opacities), confirming
significant exposure. There were 213 non-Con Edison referrals
who also reported significant occupational asbestos exposure; 106
of these had CT-scan changes consistent with exposure. Thus, 171
individuals (14.5% of our total) had confirmed asbestos exposure
based on both employment history and CT changes consistent
with exposure (Tables 1 and 2). Given the difficulty of assessing
actual asbestos exposure, this group with both occupational history
and CT changes was the group we considered to have confirmed
significant asbestos exposure.
Nodules
More than half (52.7%) of the participants had NCNs over
4 mm on either their initial or follow-up CT-scans (Table 2).
Figure 1. Histogram of the number of CTs performed per individual. Over 70% of participants had at least one follow-up CT. A total of 345
had 1 CT, 183 had 2 CTs and 654 had 3 or more CTs. Those that did not have follow-ups were individuals with no nodules on initial CT who chose not
to return or individuals who were not yet due for follow-up by the end of the study period.
doi:10.1371/journal.pone.0039403.g001
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nodules; 104 (8.7%) with one or more sub-solid (ground-glass or
mixed) nodules; and 139 (11.6%) with both solid and sub-solid
nodules. Of the individuals with solid nodules, 51.3% had only 1
nodule. Of participants with sub-solid nodules, 57.9% had only 1
lesion.
We evaluated the solid and sub-solid nodule based on their size
and changes over time. We identified 1084 solid nodules in 501
individuals and 442 sub-solid nodules in 213 individuals for whom
follow-up CTs were performed by the end of the study period. We
classified the nodules as resolved (0 mm for at least 2 consecutive
measurements), decreased (decline by at least 3 mm on subsequent
CTs), stable (less than 3 mm change on subsequent CTs) or
increased (increase by at least 3 mm on follow-up CTs) (Table 2).
Sub-solid nodules were more likely than solid nodules to change in
size (44.8% versus 15.4%). By the time of the last follow-up
included in this study, 9.7% of solid nodules and 26.2% of sub-
solid nodules had resolved in 76 and 73 individuals, respectively. A
smaller number of nodules had decreased in size, but did not
resolve. There were 37 solid nodules in 34 individuals (3.4% of
Table 1. Demographic & Clinical Characteristics of the
Screened Population at Enrollment.
Characteristic Number (%)
Gender
Male 616 (52.2)
Female 566 (47.8)
Age
Mean 63610
.74 158 (13.4)
55–74 825 (69.9)
,55 198 (16.8)
Race
White 1048 (88.7)
Non-white or Hispanic 134 (11.3)
BMI
Mean 27.965.4
Underweight (,18.5) 107 (9.1)
Normal (18.5–24.9) 332 (28.1)
Overweight (25–30) 437 (37.0)
Obese I, II, III (.30) 305 (25.8)
Tobacco Exposure
Pack-years
Mean 42623
,30 437 (36.9)
30–50 456 (38.5)
.50 291 (24.5)
Current Smoker 651 (55.0)
Second Hand Smoke Exposure 389 (28.9)
Marijuana Use (ever) 385 (32.8)
Occupational Asbestos Exposure 307 (26.0)
1st Degree Relative with Lung Cancer 228 (19.3)
Persistent Respiratory Symptoms (.3 mths)
Cough 230 (19.5)
Phlegm 220 (18.6)
Dyspnea (modified MRC scale*)
1 (mild) 316 (26.7)
2 (moderate) 99 (8.4)
3 (severe) 37 (3.1)
4 (very severe) 28 (2.4)
*MMRC dyspnea scale: 1=dyspnea with mild exertion (hurrying on level ground
or walking up a slight hill; 2=dyspnea on level ground walk slower than people
of the same age due to dyspnea, or have to stop for breath when walking at
usual pace; 3=dyspnea after walking about 100 yards or after a few minutes on
level ground; 4=too breathless to leave the house or breathless when dressing.
doi:10.1371/journal.pone.0039403.t001
Table 2. Pulmonary Function Testing and CT Results of
Screened Population.
Pulmonary Function Testing at Enrollment (NHANES)
FVC 3.72L61.04
FVC % pred. 93.0%616.6
FEV1 2.80L60.83
FEV1% pred. 90.3618.5
FEV1/FVC 75.068.4
CT Findings
Emphysema on initial CT scan 420 (35.5%)
Asbestos-related changes
(asbestosis, pleural plaques, and/or pleural
thickening)
171 (14.5%)
Nodule findings on first or subsequent CTs
No nodule 557 (47.1%)
Any nodule .4 mm 625 (52.9%)
Solid nodules only 382 (32.4%)
Sub-solid nodules only 104 (8.7%)
Both SN and sub-solid.4 mm 139 (11.6%)
Solid Nodules
Total individuals with SNs 519 (45% of total)
Solitary 266 (51.3% of SNs)
Multiple 253 (48.7% of SNs)
Total SNs (not individuals) with f/u scans 1084
Resolved on f/u 105 (9.7% of SNs)
Mixed pattern 1 (0.1%)
Decreased on f/u 25 (2.3%)
Increased on f/u 37 (3.4%)
Stable on f/u 916 (84.5%)
Sub-Solid Nodules
Total individuals with sub-solid nodules 239 (20.3% of total)
Solitary 138 (57.9% of SSNs)
Multiple
Total sub-solid nodules with f/u scans 442
Resolved on f/u 116 (26.2% of SSNs)
Mixed pattern 3 (0.7%)
Decreased on f/u 40 (9.1%)
Increased on f/u 42 (9.5%)
Stable on f/u 241 (54.5%)
Note: many patients had more than one nodule.
Abbreviations: FVC=forced vital capacity, FEV1=forced expiratory volume in
one second, SSN=Sub-solid nodule; SN=solid nodule; f/u= follow up.
doi:10.1371/journal.pone.0039403.t002
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sub-solid nodules) that increased in size. Some of these were
referred for surgery (see below); others are still under close
observation due to patient preference for a more conservative
approach. The majority of nodules remained stable: 84.5% of solid
nodules and 54.5% of sub-solid nodules.
Lung Cancer Diagnoses
We diagnosed 33 lung cancers in 30 patients. Three patients
had more than 1 site of malignancy–considered synchronous
primaries or multifocal disease. Twenty-three cases were prevalent
at the initial screen and 10 were incident lung cancers identified at
the follow up screens. Seven patients underwent surgery for
suspicious nodules that were not non-small cell or small-cell lung
cancer. The diagnoses included: granuloma, hamartoma, orga-
nizing pneumonia, mesothelioma, gastrointestinal tumor metasta-
sis, benign carcinoid and B cell non-Hodgkin’s lymphoma.
The mean age of the lung cancer patients was 69 years, and
included 11 men and 19 women (Table 3). They had a mean of
56.5 pack-years of smoking, and 17 were current smokers. Nine
patients had a history of significant occupational asbestos exposure
(average of 32 years of exposure) and 4 had asbestosis and/or
pleural plaques on CT-scan. The majority (65%) of patients had
persistent respiratory symptoms; one half had emphysema on their
CT-scans. One-fourth had a first-degree relative with a history of
lung cancer. Most (28/30) patients had multiple nodules on their
CT-scans. Nineteen cancers presented as sub-solid and 14
presented as solid nodules. The average size of the nodules was
Table 3. Lung Cancer Cases Compared with All Screened.
Lung Cancers All Screened
(n=30 pts, 33 cancers) (n=1182)
Mean Age 68.6 (range 53–79) 63
Gender 19 (63%)Female 47.8%F
BMI 27.6 (66.5) 27.9
Mean Pack Years 56.5 (620.1) 42 (623)
Current Smokers 17 (56.7%) 55.0%
Second-hand Smoke 9 (31%) 29.0%
Marijuana Use (ever) 7 (24.1%) 32.8%
Occupational Asbestos Exposure 9 (30%) 26.0%
Asbestosis or Pleural Plaques 4 (13%) 23.5%
1
st Degree Relative w/Lung Cancer 7 (24.1%) 20%
Emphysema on CT 15 (51.7%) 35.6%
Respiratory Symptoms .3 months
Cough 12 (40%) 19.5%
Phlegm 9 (30%) 18.6%
Dyspnea 19 (63.3%) 40.6%
PFT Data
Mean FVC 3.2160.8 (89.9% pred.) 93.0% pred.
Mean FEV1 2.29L60.65 (84.3% pred.) 90.3% pred.
Mean FEV1/FVC 71.769.89 7568.4
CT appearance of nodules
Sub-solid 19 (57.6%) 243 pts (20.6%)
Solid 14 (42.4%) 521pts (44.1%)
Pathology
Adenocarcinoma 26*
Squamous Cell 2
Small Cell Lung Cancer 3*
Non-Small Cell NOS 2
Stage at Diagnosis
IA 25
IB 2
IIA 1
IV 4
Incidence/prevalence 10/23*
Mean disease-free survival of 30 patients 45.8 months
*3 patients diagnosed with 2 primaries. 2 with synchronous adenoca, 1 with prevalence adenocarcinoma and incidence small cell.
doi:10.1371/journal.pone.0039403.t003
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histological types of cancer were 26 adenocarcinomas, 2
squamous-cell carcinomas, 3 small-cell carcinomas, and 2
undifferentiated non-small cell carcinomas. More than 80% of
the cancers were diagnosed at stage I. There was no association
between the appearance (solid versus sub-solid) of the nodule and
the pathologic type, stage at diagnosis or exposure history.
We categorized cancers as incident if the nodule was not present
on the baseline CT-scan, and prevalent if a nodule observed at
baseline CT was eventually diagnosed as malignant. Twenty-one
patients (23 cancers) had nodules on their initial CTs that were
found to be cancer (Table 4). Six of these were diagnosed after
identification of a suspicious nodule more than 1 cm in size on the
initial CT; 4 were diagnosed after the first follow-up CT for a
suspicious nodule seen on the baseline CT demonstrated growth.
Twelve patients (13 cancers) had nodules on their initial CT that
were followed, remained stable for varying lengths of time, and
then were noted to increase in size or density (Table 4 and
Figure 2). All but one of these cases were stable for more than 3
years prior to diagnosis. The course of these apparently more
indolent cases is shown in Figure 2:7 nodules increased in size, 1
increased in density, and 5 increased in both size and density.
Three of the patients initially refused surgery; 3 had negative PET
scans and were followed. The prevalence cases diagnosed after
.6 mth follow-up were initially smaller than the prevalent cases
diagnosed within 6 months (mean 12.8 mm versus 19.1 mm), and
were followed for a mean of 50.3 months and underwent an
average of 7.8 CTs. Eleven out of 13 of these cases presented as
ground-glass nodules, 12 out of 13 were adenocarcinomas.
Ten patients had incident cancers that developed during the
course of the study (Table 4). The average period of observation
prior to the appearance of the nodule was 63 months. The average
length of time between a prior CT and appearance of the
malignant nodule was 13.8 months (range 6–24). Some of these
patients were being followed for other nodules; some were
undergoing repeat annual or biennial screening CTs. The mean
size of the nodule at diagnosis was 13.6 mm. All the cases of small-
cell lung cancer were diagnosed as incident cases.
There was no association between the appearance of the
nodules (solid versus sub-solid), or the overall outcome and
whether the cancer was incident or prevalent or diagnosed before
or after 6 months of follow-up (Table 4). Although overall survival
was not significantly different, local recurrences and second
primaries occurred in 3/12 individuals in the .6 mth prevalence
group. There is not as long a follow-up period for many of the
incident cases, but the data suggests that these are more aggressive
cancers.
Models for Assessment of Nodules–two Case-control
Studies
We compared individuals with nodules on their initial CT with
individuals who had no nodules on any of their CTs, and then
examined associations of the presence of a solid or sub-solid
nodule with patient characteristics. In these polytomous logistic
regression analyses, increasing age, male gender, and history of
emphysema were the only significant predictors of the presence of
a solid or sub-solid nodule (Table 5). When we stratified by gender,
in men, older age was a risk factor for the presence of both solid
and mixed nodules; the presence of emphysema was a risk factor
for solid nodules. In women, the only association found was
between older age and the presence of mixed nodules. Of note,
smoking history (years of smoking, cigarettes smoked per day,
pack-years, second-hand smoke exposure and current smoking
status), asbestos exposure and presence of respiratory symptoms
were not significantly associated with nodule class in our
multivariable analyses.
We compared the individuals diagnosed with cancer (n=30) to
those with only presumed-benign nodules (n=128 subjects) to
identify risk factors for nodules that may represent lung cancer
(Table 6). Presumed-benign nodules were defined as solid or sub-
solid nodules that resolved on follow-up and solid nodules that
decreased in size or remained stable for more than 2 years. We
excluded persistent sub-solid nodules from this group, since we
and others [16,17] have found that a significant percentage of sub-
solid or ground-glass nodules represent malignancy. As noted
above, 11 of our lung cancer cases presented as ground-glass
Table 4. Characteristics of Prevalent versus Incident Lung Cancers.
Size & CT Density
at Enrollment
Size & CT Density
at Diagnosis
Mean Time Prior
to Diagnosis Histology
Stage at
Diagnosis
Median Disease-Free
Survival After Diagnosis,
& Outcomes
All cancers (33) (includes
3 synch. primaries)
10.8 mm
9S N
14 SSN
18.6 mm
19 SN
14 SSN
39.8 mths 26 adeno
2 squamous
3 small cell
2 NSCLC
26 Stage I
2 Stage II
4 stage IV
42 (range 6–113) mths
5 expired (lung ca.)
4 recurrences (local)
1 lost to f/u
Prevalence cancers dx
,6 mths (10)
19.1 mm
7S N
3 SSN
21.6 mm
7S N
3 SSN
2.4 mths 9 adeno
1 NSCLC
7 Stage I
2 Stage II
1 Stage IV
81.5 (11–113) mths
2 expired (lung ca.)
1 recurrence (local)
Prevalence cancers dx
.6 mths (13)
12.8 mm
2S N
11 SSN
20.1 mm
7S N
6 SSN
50.3 mths 12 adeno
1 squamous
13 stage I 47 (5–96) mths
1 expired (lung ca.)
3 recurrences (local)
1 expired (cva)
Incidence cancers (10) Not present
on initial CT
13.6 mm
5S N
5 SSN
63.5 mths 5 adeno
1 squamous
3 small cell
1 NSCLC
6 stage I
3 stage IV
13 (6–33) mths
2 expired (lung ca)
1 lost to f/u
*Numbers equal 33 cancers in 30 patients, since three patients had more than one diagnosis of lung cancer (synchronous or second primaries).
Abbreviations: adeno=adenocarcinoma, NSCLC=non-small cell lung cancer not otherwise specified, SN=solid nodule, SSN=sub-solid nodule, ca.=cancer,
cva=cerebrovascular accident.
doi:10.1371/journal.pone.0039403.t004
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diagnosis. Some individuals had multiple nodules–the benign
nodule group had only presumed-benign nodules.
The FVC and FEV1 percent-predicted were significantly lower
and the mean pack-years smoking was significantly higher for
cancer subjects than for individuals with benign nodules. The ratio
of FEV1/FVC was also lower, and there was more emphysema on
CT-scan in the lung cancer patients, although these differences
were not statistically significant. Compared with individuals with
benign nodules, individuals with lung cancer more frequently had
multiple nodules (average total number 5.3 versus 1.7), which
tended to be sub-solid density (average number of sub-solid
nodules 3.1 versus 0.2) and larger in size (average size 8.1 mm
versus 6.3 mm). No significant association was found for the other
variables analyzed, which included age, gender, BMI, family
cancer history, asbestos exposure, and respiratory symptoms.
Figure 2. Clinical Course of Prevalent Lung Cancer Cases Diagnosed After More Than 6 Months of Monitoring. Graphic representation
of the course of 13 lung cancer cases in 12 patients, plotted by months from enrollment. Each circle represents a point in time relative to enrollment
when a CT scan was performed. Surgical resection was performed after the last point in each case. The size of the circle is proportional to the size of
the nodule on CT scan. The shading indicates the density of the nodule: grey represents ground-glass density; darker shading represents mixed
density and black represents more solid density. 12/13 cases were adenocarcinomas. The asterisk indicates the only patient in this group who has
expired due to lung cancer (patient 1).
doi:10.1371/journal.pone.0039403.g002
Table 5. Odds Ratios for Risk Factors for the Presence of Nodules on Initial CT Scan*.
Parameter Category OR 95% OR Limit-Lower
95% OR
Limit-Upper p-value
All participants Gender
(female vs. male)
SSN 0.50 0.31 0.80 0.004
Age
(older vs. younger)
Mixed 1.06 1.04 1.09 ,.0001
Emphysema
(present vs. absent)
SN 1.50 1.10 2.03 0.01
Emphysema
(present vs. absent)
SSN 1.68 1.05 2.70 0.03
Men Age (older vs. younger) SN 1.03 1.01 1.05 0.011
Age (older vs. younger) Mixed 1.07 1.03 1.10 ,.0001
Emphysema (present vs. absent) SN 1.97 1.31 2.95 0.001
Women Age (older vs. younger) Mixed 1.06 1.03 1.09 0.0002
*Stepwise logistic regression, with OR calculated by gender, presence of emphysema or current age versus 1 year increase in age. For example: OR shows increased age
to be a significant risk factor for nodules versus the reference parameter, younger age. Only significant predictors for each category are included.
Abbreviations: SN=solid nodule, SSN=sub-solid nodule.
doi:10.1371/journal.pone.0039403.t005
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As part of a lung cancer biomarker epidemiological and
validation center, we followed 1182 individuals at high-risk for
lung cancer due to smoking and other exposures with serial CT-
scans over a period of 10 years. We found that a high percentage
(52%) of our participants had NCNs, and we diagnosed 30 cases of
lung cancer in subjects enrolled over this 10-year period. We
conducted two case-control studies: first, a comparison of
individuals with NCNs to those without nodules, and second, a
comparison of patients diagnosed with cancer to individuals with
benign nodules. Risk factors for the presence of NCNs on initial
screening CT were older age, male gender, and emphysema (in
men). When we compared lung cancer patients and individuals
with presumably benign nodules, we found that lung cancer
patients had significantly more smoking history, lower FEV1 and
FVC, and had more and larger NCNs–especially sub-solid
nodules. Our lung cancer cases had more emphysema than the
group with no nodules, but not more compared to the benign
nodules group. Although asbestos exposure was not associated
with an increased risk of nodules, 9 of 30 patients with lung cancer
had asbestos exposure for a mean of 32 years and 4 had CT-scans
with asbestos-related changes. The great majority of the nodules in
our study remained stable or resolved, and only a small percentage
(3.4% of solid nodules and 9.6% of sub-solid nodules) grew.
We diagnosed 23 prevalent cancers and 10 incident cancers. Of
the prevalent cancers, 12 were present on initial CT, but remained
stable for over 3 years prior to the diagnosis of lung cancer. These
cases were all stage I, and 11 were adenocarcinomas. The stage at
diagnosis and outcome did not differ in this indolent-prevalent
group compared with the standard prevalence and incidence
groups. This data suggests that some nodules considered benign
after several years of stability on CT-scan are malignant, and that
delayed diagnosis may not affect outcome. Of the 10 incident lung
cancers, 9 were diagnosed after more than 3 years of CT-scans
without suspicious findings.
CT screening trials worldwide have encountered the same
issues: large numbers of non-specific nodules are discovered,
necessitating repeated CTs or invasive procedures [10,19]; and it
has also been difficult to demonstrate a mortality benefit due to the
non-randomized nature of most trials, and the possibility of over-
diagnosis of indolent cancers [20,21]. Japanese investigators
pioneered low-dose CT population screening. Studies in Japan
of CT screening have reported overall cancer detection rates of
about 0.4%, with about 90% of the cancers detected at Stage 1
[22,23]. In these studies, the risk factors for malignant outcome of
ground-glass nodules were increased initial size, part-solid
appearance, and a family history of lung cancer [16,17,24]. The
percent malignancy of the ground-glass lesions ranged from 21%–
43% for nodules less than 10 mm. Similarly, CT screening trials in
Europe [25–31] and the United States [9–11,32–41] have
reported cancer detection rates from 0.9%–4.7%, and NCN rates
from 23% to 66%.
The specter of over-diagnosis and lead-time bias has also
haunted CT screening trials. When Bach and colleagues evaluated
3 single-arm CT-scan screening studies from the Mayo Clinic,
Milan, Italy, and the Moffitt Cancer Center, they found no
evidence of lung cancer deaths being averted [41]. They
concluded that screening was detecting slow-growing malignancies
resulting in lead-time bias, and that CT screening could not detect
the aggressive lung cancers that cause higher early mortality. The
recent analysis of a randomized Danish lung cancer screening trial
also showed a stage shift with CT screening but no improvement
in lung cancer mortality [42]. In contrast, as mentioned, the
NLST found that screening with low-dose chest CTs can identify
early lung cancers and decrease lung cancer mortality, but at the
cost of large numbers of non-specific NCN and a 96% false-
positive rate [12].
These findings suggest that while lung cancer CT screening can
detect early lung cancer and improve lung cancer mortality, it
remains an imperfect method of lung cancer screening. A large
number of non-specific NCN are detected, which require follow-
up, and a disproportionate number of slow-growing tumors are
identified. The challenge therefore, is to develop a screening
strategy that will identify those at highest risk of lung cancer, detect
small lung nodules in these individuals, specify whether the nodule
is malignant, and distinguish those malignant nodules that will
progress from those that may be more indolent and could be
managed more conservatively.
Analyses of the published trials have tried, as we did, to identify
risk factors for lung cancer in the screened populations, and factors
that may distinguish malignant from benign nodules. Lindell and
colleagues emphasized size, solid or semi-solid appearance, and
growth rates as important for lung cancer determination [43]. A
Spanish multivariate analysis found that emphysema but not
Table 6. Lung Cancers Cases versus Participants with Benign Nodules: Comparisons at initial Visit.
Variable
Lung cancer cases
(n=30)
Subjects with Benign nodules*
(n=128) P-value**
Mean FVC% predicted 89.9 96.5 0.0129
Mean FEV1% predicted 84.3 93.9 0.0068
Mean FEV1/FVC 71.7 75.7 0.1498
Emphysema 52% 43% 0.3932
Mean Pack years 56.5 40.0 ,0.0001
Current smoker 56% 55% 0.3619
Mean # of solid nodules 2.2 1.5 0.032
Mean # of sub-solid nodules 3.1 0.2 ,0.0001
Mean total number of nodules 5.3 1.7 ,0.0001
Mean size of nodules 8.1 6.3 P,0.001
*Benign nodules = solid nodule stable .2 yrs, or any nodule (solid or sub-solid) that resolved.
**Average scores were used for ties, Kruskal-Wallis test.
doi:10.1371/journal.pone.0039403.t006
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cancer [44]. In an analysis of the University of Pittsburgh CT-scan
screening cohort, increasing GOLD class was associated with lung
cancer, as was radiographic emphysema [40]. An analysis the
Italian COSMOS screening trial determined that the strongest
predictors of lung cancer risk at screening entry were age and
smoking duration and intensity [45]. The strongest predictors of
lung cancer after first screening were the presence of emphysema
and nodules on initial CT–larger nodule size and non-solid nodule
type indicated the highest risk. A meta-analysis in 2008 supported
the increased risk of lung cancer in individuals with reduced FEV1
[46]. Maldonado et al. found no association between emphysema
and lung cancer in a nested case-control study using quantitative
emphysema analysis [47]. A recent meta-analysis found that
emphysema was associated with increased risk of lung cancer only
in studies where the assessment of emphysema was made visually,
and not by automated densitometric assessment. [48] This finding
may explain some of the conflicting results in the literature
regarding emphysema and lung cancer risk. The finding that the
presence of multiple sub-solid nodules increases the risk of lung
cancer may reflect the increased risk associated with lung scarring
[49].
Our study confirms that increased age and emphysema are risk
factors for the presence of NCNs on CT-scan. We also found that
decreased FEV1 and FVC, smoking history and the presence of
multiple sub-solid nodules were the strongest predictors that an
individual with NCNs will be diagnosed with lung cancer. This
data can be used to begin to refine the ideal population for
screening. Age, smoking history, and presence of emphysema
should all be considered when deciding whether to recommend
lung cancer screening. After a small non-specific NCN is identified
on initial screening CT, reduced lung function, (particularly FEV1
and FVC), increased smoking history, sub-solid or mixed density
of the nodule and increased size or number of nodules increase the
possibility that the nodule may be malignant, and should mandate
closer monitoring.
Because of the design of our study, we followed individuals with
no nodules or stable nodules for a period of up to 10 years. This
prolonged follow-up led to additional insights into the issues of
over-diagnosis and lead-time bias in lung cancer screening. More
than 1/3 of the cancers we diagnosed were indolent adenocarci-
nomas that remained stable on CT scan for more than 3 years,
and were still stage I at diagnosis. Early diagnosis of these indolent
cancers may not affect mortality–the perceived improved survival
may reflect over-diagnosis of indolent non-lethal cancers or lead-
time bias due to the earlier diagnosis of cancers that would have
been diagnosed at an early stage anyway. The other striking
finding of our study was that all but one of the incident cancers
were diagnosed after more than 3 years of normal screening CTs.
Based on the NLST, the current recommendation is to perform 3
yearly CTs in high-risk individuals. Our findings suggest that this
recommendation may be too short.
As CT screening for lung cancer becomes widespread, we still
face many uncertainties. The optimal CT screening schedule, both
to follow NCNs and to monitor high-risk individuals without
suspicious findings, remains to be defined. Will early diagnosis of
the indolent cases change the prognosis? Improved risk stratifica-
tion will address some of these issues. A breath or blood
biomarker, such as a panel of protein markers, auto-antibodies,
microRNAs or methylation patterns, would also be useful in,
defining the nature of indeterminate NCN and distinguishing the
more aggressive from the indolent lung cancers [50].
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